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Neurofibromatosis 1 is a genetic disease characterized by cutaneous, neurological and 
osseous abnormalities. About 20% of patients develop plexiform neurofibroma, resulting 
in impaired quality of life. To evaluate distribution of diffuse plexiform neurofibroma on 
the body surface, a retrospective study was conducted for 354 patients with 
neurofibromatosis 1 from 2007 to 2018 in Japan. We investigated a total of 40 patients 
with clinically apparent superficial diffuse plexiform neurofibroma. In the cases evaluated, 
57.4% of the diffuse plexiform neurofibromas were located on the trunk, 19.2% were on 
the head and neck, 12.8% were on the lower limbs and 10.6% were on the upper limbs. 
Remarkably, 75.0% of the diffuse plexiform neurofibromas were located on the dorsal 
side. The frequency was significantly higher on the trunk than on the head and neck (p = 
0.026). Our findings provide useful information for giving attention to the high possibility 
of diffuse plexiform neurofibroma on the dorsal side before the progression in childhood 
and for the future treatment in neurofibromatosis 1. 
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Neurofibromatosis 1 (NF1) is an autosomal dominant genetic disease characterized by 
café-au-lait spots, neurofibromas, freckling, optic gliomas, Lisch nodules and bone 
deformity.1 It is caused by mutation of the NF1 gene on chromosome 17q11.2.2 The 
worldwide prevalence of NF1 is approximately 1 in 3000-4000 individuals with nearly 
100% penetrance.3 Diffuse plexiform neurofibroma (PN), known as elephantiasis 
neurofibroma or patchydermatocele, is an overgrowth of cutaneous tissue associated with 
proliferation of neurofibromas.4 Complications of diffuse PN are limited limb movements, 
neurological deficits, bleeding due to trauma, malignant transformation and 
disfigurement.5 It often causes cosmetic and functional disturbances, resulting in impaired 
quality of life.6 To our knowledge, there have been a few reports on the assessment of 
deeply located PN that was revealed by magnetic resonance imaging (MRI) .7-9 However, 
the distribution of diffuse PN on the body surface has not been clarified. Therefore, we 
studied the features of superficial diffuse PN in patients with NF1. 
 
PATIENTS AND METHODS 
Study population (Patients) 
A retrospective study was conducted for 354 NF1 patients referred to the Dermatology 





University Hospital between 2007 and 2018. We investigated a total of 40 NF1 patients 
with clinically apparent diffuse PN that could be recognized by physical examination (16 
men and 24 women). All of the patients were evaluated by expert dermatologists and met 
the diagnostic criteria by National Institutes of Health for NF1.10 Patients with mosaic 
NF1 (localized NF1)11 were excluded from our study. Demographic and clinical 
information on the age and sex of patients and the size and number of diffuse PNs was 
obtained from medical records and photographic images. In this study, we included the 
hanging tumors (>5cm in size) with pigmented macule on the surface skin in most cases 
as diffuse plexiform neurofibroma. Subcutaneous nodular plexiform neurofibroma 
(solitary intraneural neurofibroma) was excluded from this study. For each patient, we 
evaluated the site of diffuse PN on the body surface based on the ratio of distribution of 
tumors and classified PNs into four sites: head and neck, trunk, upper limbs and lower 
limbs. Image examinations such as MRI were not necessarily performed. The study 
protocol was approved by the Ethics Committee of Tottori University Hospital (No. 
1704A005) and the Ethics Committee of Fukuoka University Hospital (No. 17-4-03). 
 
Statistical analysis 





(ventral/dorsal side) between the head and the neck and trunk. P-values < 0.05 were 
considered statistically significant. All statistical analyses were conducted using EZR 
(Saitama Medical Center, Jichi Medical University, Saitama, Japan), which is a graphical 
user interface for R (The R Foundation for Statistical Computing, Vienna, Austria, version 
2.13.0). More precisely, it is a modified version of R commander (version 1.32) designed 
to add statistical functions frequently used in biostatistics. 
 
RESULTS 
We evaluated 40 NF1 patients (16 men and 24 women [no pregnancy]; median age, 30 
years, age range, 0-65 years) with diffuse PN on the body surface. There were 47 PNs in 
the 40 patients. A representative case (with 2 superficial diffuse PNs on the lower leg) is 
shown in Fig. 1. Among these cases, 57.4% of the diffuse PNs were located on the trunk, 
19.2% were on the head and neck, 12.8% were on the lower limbs and 10.6% were on the 
upper limbs (TableⅠ). We mapped the distribution of diffuse PNs on the body surface per 
patient as shown in Fig. 2. and evaluated the predilection sites of the head and neck and 
the trunk in detail. In addition, we classified the location as the dorsal or ventral side 
based on the ratio of distribution of tumors on the head and neck and the trunk (Tumors 
on extremities were excluded from analysis). Interestingly, 75.0% (27/36) of the diffuse 





than on the head and neck (p = 0.026).  
 
DISCUSSION 
NF1 has cutaneous, neurological and osseous abnormalities, and one of the major features 
of NF1 is PN (nodular and diffuse types).1 We previously reported that 21% of NF1 
patients referred to our dermatology department had diffuse PNs.12 There have been some 
studies that focused on deeply located PNs that were investigated by MRI.7-9 Mautner et 
al. proposed 3 different growth patterns of PN (superficial, displacing and invasive 
growth patterns) and reported that the most frequent site of PNs was the head and neck 
region (36%) in 256 tumors of 202 NF1 patients (mean age, 28.3 years).7 They found that 
54% of the PNs located on the head and neck region showed an invasive growth pattern. 
On the other hand, Tucker et al. reported that the most frequent site of PNs was the 
extremities or the spine (30% each) in 44 tumors of 34 NF1 patients (median age, 10 
years) .8 Nguyen et al. showed that the most frequent site was the trunk (38.4%) in 73 
PNs of 37 NF1 patients (mean age, 10.5 years).9 In our study, 57.4% of the diffuse PNs 
were found to be located on the trunk by evaluation of body surface PNs. Since we could 
not evaluate deeply located tumors such as tumors in the nearby spine, the relative ratio 





related to referral facilities (i.e., department of maxillofacial surgery, department of 
medical genetics, MRI institute or department of dermatology). Some patients with severe 
facial diffuse PN might be referred to another department. In the present study, we 
focused on diffuse PNs that had developed on the surface of the body and found that the 
75.0% of diffuse PNs were located on the dorsal side, especially on the dorsal side of the 
trunk. It is well known that diffuse plexiform neurofibroma is a congenital tumor. 
However, it is possible not to find the tumor early in childhood because only large 
pigmented macules were detectable in some patients. Since the tumor increase in size, 
especially in childhood, it is important for clinician to keep the high possibility of dorsal 
distribution of diffuse plexiform neurofibroma in mind before the progression in the 
follow-up period. 
It is well known that Schwann cells play an important role in the pathogenesis of 
neurofibroma in NF1.13 It has been reported that complete loss of NF1 at the late 
precursor-early immature Schwann cell stage causes dissociation of non-myelinating 
Schwann cells from Remak bundles, resulting in the development of PN.14 Schwann cells 
are thought to originate from the neural crest. The neural crest is a transient embryonic 
state that arises between the newly formed ectoderm and the neural tube. While the neural 





migrate from the dorsal region to the ventral region and differentiate into cells of both 
mesodermal and ectodermal components. Therefore, we speculate that loss of function of 
the second NF1 allele in Schwann cells during migration is related to the frequent 
anatomical location of diffuse PN on the dorsal side of the trunk. 
There is a number of limitations in our study. Since we investigated diffuse PN that 
developed on the body surface, image analysis was not necessarily performed. Therefore, 
we could not evaluate the volume of diffuse PN. In addition, the number of patients was 
relatively small because the survey was limited to the field of dermatology.  
Recent clinical trials have shown promising success in treatment with the MAP kinase 
inhibitor selumetinib in children with PN.15 Our findings provide useful information for 
giving attention to the high possibility of diffuse PN on the dorsal side in early childhood 
before progression and for treatment of NF1 in the future. 
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Fig. 1. A representative case of NF1. There were two superficial diffuse plexiform 
neurofibromas on the lower limb (right thigh and knee).  






Table 1. Clinical features of superficial diffuse plexiform neurofibromas in our study. 
 
Location 




Head and neck  9 (19.2%) 5 4 
Trunk 27 (57.4%) 4 23 
Upper limbs 5 (10.6%) NA NA 
Lower limbs 6 (12.8%) NA NA 
  9 27* 
N.A., not applicable. 
* p = 0.026 
 
